Yükleniyor... / Loading...
This study retrospectively investigates how often NTRK gene fusions occur in solid tumors. People aged 1 month and older with advanced solid tumors such as soft tissue sarcoma, melanoma, colorectal cancer, and non-small cell lung cancer were included. This observational study, with no intervention, was carried out as a study with no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Age ≥ 1 month. * Subject has/had a histologically or cytologically confirmed diagnosis of solid tumor including but not exclusively: soft tissue sarcoma, BRAF wild type melanoma, KRAS wild-type colorectal cancer, central nervous system, EGFR-wild type non-small cell lung cancer. * Subject has locally advanced/unresectable or metastatic disease. * Subject has received at least one systemic anti-cancer therapy for locally advanced/unresectable or metastatic disease for which there is available outcome information in terms of PFS, or the latter can be estimated based on the subject's records. * Subject has tumor material available for immunoscreening (IHC for NTRK gene fusions). * Written and voluntary informed consent understood, signed and dated, or a waiver of consent is granted according to French régulations. Exclusion Criteria: • Subjects who have not yet received or completed at least one systemic anti-cancer therapy for locally advanced/unresectable or metastatic cancer.